ТУРЛИ ЭТИОЛОГИЯЛИ ИШЕМИК ИНСУЛЬТДА ЯЛЛИҒЛАНИШ БИОМАРКЕРЛАРИ ВА ИНСУЛИН РЕЗИСТЕНТЛИГИ
##article.subject##:
ўткир ишемик инсульт, инсулинга резистентлик, яллиғланиш биомаркерлари, TOAST, кардиоэмболик инсульт##article.abstract##
Ушбу тадқиқот турли этиологияли ишемик инсультнинг ўткир даврида яллиғланиш биомаркерлари даражасидаги фарқларни ўрганади ҳамда инсулин резистентлигини (IR) муҳим метаболик омил сифатидаги ролини баҳолайди. Тадқиқотда ICAM-1, hs-CRP, SII ва NLR кўрсаткичлари инсультнинг турли типлари ўртасида таққосланди ва уларнинг IR билан боғлиқлиги таҳлил қилинди. Натижалар шуни кўрсатдики, кардиоэмболик инсультларда яллиғланиш фаоллиги юқорироқ бўлиб, лакунар инсультларда биомаркерлар даражаси пастроқ кузатилди. Бундан ташқари, беморларда IR тез-тез учраб, яллиғланиш маркерларининг ошиши билан боғлиқ экани аниқланди, бу эса унинг томир шикастланишини кучайтиришда синергетик роль ўйнашини кўрсатади.
Библиографические ссылки
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35-41.
Ageno W, Finazzi S, Steidl L, et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med. 2002;162(22):2589-2593.
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009;27(5):493-501.
Banks JL, Marotta. CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38(3):1091-1096.
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics–2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.
Boos CJ, Anderson RA, Lip. GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27(2):136-149.
Cai Z, He W, Zhuang F- J, et al. The role of high high- sensitivity C- reactive protein levels at admission on poor prognosis after acute ischemic stroke. Int J Neurosci 2019;129:423–9.
Eikelboom JW, Hankey GJ, Baker RI, et al. C- reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis 2003;12:74–81.
Ertl M, Meisinger C, Linseisen J, Baumeister SE, Zickler P, Naumann M. Long-term outcomes in patients with stroke after in-hospital treatment-study protocol of the prospective stroke cohort Augsburg (SCHANA study). Medicina (Kaunas). 2020;56(6):280.
Guo Y, Lip GY, Apostolakis. S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263-2270.
Harpaz D, Seet RCS, Marks RS, Tok AIY. Blood-based biomarkers are associated with different ischemic stroke mechanisms and enable rapid classification between cardioembolic and atherosclerosis etiologies. Diagnostics (Basel). 2020;10(10):804.
Jickling GC, Sharp. FR. Biomarker panels in ischemic stroke. Stroke. 2015;46(3):915-920.
Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke. 1999;30(8):1534-1537.
Laloux P, Galanti L, Jamart. J. Lipids in ischemic stroke subtypes. Acta Neurol Belg. 2004;104(1):13-19.
Liu LB, Li M, Zhuo WY, Zhang YS, Xu AD. The role of hs-CRP, Ddimer and fibrinogen in differentiating etiological subtypes of ischemic stroke. PloS One. 2015;10(2):e0118301.
Montaner J, Ramiro L, Simats A, et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol. 2020;16(5):247-264.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
Sonderer J, Katan Kahles. M. Aetiological blood biomarkers of ischaemic stroke. Swiss Med Wkly. 2015;145:w14138.
Stanimirovic DB, Wong J, Shapiro A, et al. Increase in surface expression of ICAM- 1, VCAM- 1 and E- selectin in human erebromicrovascular endothelial cells subjected to ischemia- like insults. Acta Neurochir Suppl 1997;70:12–6.
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.
Wei P, Han B, Zhang W- J, et al. Effect of Ticagrelor on the serum level of Hs- CRP, ESM- 1 and short- term prognosis of patients with acute STEMI. Exp Ther Med 2017;13:604–8.
Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C- reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459–64.
Yu B, Yang P, Xu X, et al. C- reactive protein for predicting all- cause mortality in patients with acute ischemic stroke: a meta- analysis. Biosci Rep 2019;39:BSR20181135.
Yuan BB, Luo GG, Gao JX, et al. Variance of serum lipid levels in stroke subtypes. Clin Lab. 2015;61(10):1509-1514. doi:10.7754/ clin.lab.2015.150118
Zambrelli E, Emanuele E, Marcheselli S, Montagna L, Geroldi D, Micieli G. Apo(a) size in ischemic stroke: relation with subtype and severity on hospital admission.Neurology.2005;64(8):1366-1370.
